Herpes simplex prophylactic vaccine - Xenova

Drug Profile

Herpes simplex prophylactic vaccine - Xenova

Alternative Names: DISC-PRO

Latest Information Update: 13 Sep 2010

Price : $50

At a glance

  • Originator Xenova Group
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Herpes simplex virus infections

Most Recent Events

  • 01 Sep 2005 Celtic Pharma acquires Xenova Group
  • 01 Sep 2005 Discontinued - Phase-I for Herpes simplex virus infections in United Kingdom (SC)
  • 29 Jul 2004 Suspended - Phase-I for Herpes simplex virus infections prevention in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top